Coherus Biosciences | CHRS - Selling And Administration Expenses


Coherus Biosciences reported $26.02M in Selling and Administration Expenses for its fiscal quarter ending in March of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
Amgen USD 1.94B 237M Dec/2025
Baxter International USD 761M 53M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Coherus Biosciences USD 26.02M 8.57M Mar/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Fujifilm JPY 215.83B 2.93B Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Merck USD 2.85B 215M Dec/2025
Myriad Genetics USD 129M 1.3M Sep/2025
Pacira USD 91.87M 70K Dec/2025
Perrigo USD 255.9M 10.2M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xencor USD 17.04M 70.74M Dec/2025
Zoetis USD 619M 40M Dec/2025